• EPZ-6438 (SKU A8221): Reliable EZH2 Inhibitor for Lab Succes

  2026-04-29

  This article provides scenario-driven answers for biomedical researchers and lab technicians facing real-world challenges in epigenetic cancer research. By leveraging EPZ-6438 (SKU A8221), a highly selective EZH2 inhibitor, the article demonstrates how to achieve reproducible, data-backed results in cell-based assays. Practical protocol guidance and comparative vendor insights empower scientists to make informed, evidence-based decisions.

• Low-Dose Orlistat Enhances Oxaliplatin Efficacy in Colorecta

  2026-04-28

  This study demonstrates that low-dose orlistat significantly intensifies the antitumor effect of oxaliplatin in colorectal cancer models by promoting apoptosis. The findings provide mechanistic insights and experimental benchmarks for overcoming chemoresistance in preclinical and translational research.

• Cy5-UTP: Mechanistic Precision for Translational RNA Science

  2026-04-28

  This thought-leadership article examines how Cy5-UTP (Cyanine 5-UTP) catalyzes a paradigm shift in RNA probe synthesis for advanced translational research. By weaving mechanistic insights from polyelectrolyte nanoparticle engineering into the practical realities of in vitro transcription RNA labeling and fluorescence in situ hybridization (FISH), we offer actionable strategies for researchers aiming to unlock the full potential of RNA analytics. Drawing on recent high-throughput structural studies and APExBIO’s product intelligence, we map a credible path from chemical rationale to translational relevance—while explicitly distinguishing this guidance from conventional product-focused content.

• Ceramide Metabolism Drives Fish Nodavirus Replication via Au

  2026-04-27

  This study defines how red-spotted grouper nervous necrosis virus (RGNNV) manipulates ceramide metabolism in host cells to enhance its replication, primarily by promoting autophagy. The findings shed light on sphingolipid pathways as pro-viral mechanisms, presenting new directions for neurodegenerative disease modeling and antiviral research.

• Boc-D-FMK in Apoptosis Research: Protocols, Applications & T

  2026-04-27

  Boc-D-FMK stands out as a pan-caspase inhibitor enabling reproducible apoptosis and inflammation workflows, especially in renal and hepatic models. This article details stepwise protocol guidance, troubleshooting insights, and how APExBIO’s formulation supports robust experimental outcomes across cell-based and animal studies.

• Pexmetinib (ARRY-614): Optimizing Dual Inhibition in Cytokin

  2026-04-26

  Pexmetinib (ARRY-614) empowers researchers with precise, dual-targeted inhibition of p38 MAPK and Tie2, enabling robust suppression of inflammatory cytokines in challenging cell-based and translational workflows. Recent structural insights and protocol refinements position this APExBIO compound as the gold standard for reproducible cytokine modulation in myelodysplastic syndromes and inflammation models.

• Prestained Protein Marker (Triple Color, EDTA Free, 10-250 k

  2026-04-25

  The Prestained Protein Marker (Triple color, EDTA free, 10-250 kDa) is designed for precise molecular weight estimation and transfer efficiency verification in SDS-PAGE and Western blot workflows. Its triple color bands and EDTA-free formulation support compatibility with phosphoprotein analysis and fluorescent imaging. This product should not be used for applications requiring quantitation by total protein staining, or in workflows that require chelators for protease inhibition.

• PYR-41, Inhibitor of Ubiquitin-Activating Enzyme E1: Workflo

  2026-04-24

  PYR-41, a selective inhibitor of Ubiquitin-Activating Enzyme E1, empowers researchers to dissect ubiquitin-proteasome system regulation and NF-κB pathway dynamics in both in vitro and in vivo models. This guide details actionable workflows, troubleshooting strategies, and translational insights, anchored to cutting-edge immuno-oncology research.

• AZD0156: Strategic ATM Kinase Inhibition for Translational R

  2026-04-24

  This article provides a thought-leadership perspective on AZD0156, a highly selective ATM kinase inhibitor, integrating mechanistic insights, experimental guidance, and strategic recommendations for translational cancer researchers. It contextualizes the product within the evolving landscape of DNA damage response inhibition and highlights its differentiation, clinical potential, and protocol considerations.

• Applied Use of JNJ-26481585 (Quisinostat) in Cancer Research

  2026-04-23

  JNJ-26481585 (Quisinostat) is a powerful HDAC inhibitor revolutionizing the study of tumorigenesis and therapeutic resistance. This article details workflow integration, troubleshooting, and data-driven strategies for maximizing its impact in apoptosis induction and tumor growth inhibition assays.

• Tubastatin A: HDAC6 Inhibitor Protocols and Cardiac Use-Case

  2026-04-23

  Tubastatin A, a potent HDAC6 inhibitor, is propelling research in cardiac protection, inflammation, and cancer biology with unmatched selectivity. This article demystifies its bench applications, workflow optimizations, and troubleshooting strategies—grounded in cutting-edge translational evidence.

• Amine Chemistry in Polymer Micelles Tunes mRNA Lung Delivery

  2026-04-22

  This study systematically investigates how amine type and side-chain structure in cationic polymer micelles direct mRNA binding, cellular uptake, and lung-selective delivery. Machine learning analysis reveals that specific amine modifications in micelle design critically balance delivery efficiency, functional mRNA release, and cell viability, providing data-driven design rules for targeted mRNA therapeutics.

• Verbascoside: Redefining PKC/NF-κB Inhibition for Translatio

  2026-04-22

  This thought-leadership article by APExBIO’s scientific marketing head explores how Verbascoside’s targeted inhibition of PKC and NF-κB signaling is catalyzing translational advances in osteoclastogenesis, neuroinflammation, and bone metabolism research. Drawing from pivotal preclinical data, emerging workflow best practices, and a landmark neurobiology study on TMJ inflammation-induced depression, this piece provides actionable strategic guidance for researchers seeking to bridge molecular insights with clinical innovation.

• SGI-1027 and Everolimus Synergy via Lysosomal Permeability i

  2026-04-21

  This study demonstrates that the DNMT1 inhibitor SGI-1027 induces methuosis and, when combined with everolimus, synergistically enhances apoptosis and pyroptosis in renal cancer cells by increasing lysosomal membrane permeability. The findings offer a mechanistic basis for overcoming everolimus resistance in advanced renal cell carcinoma and inform strategies for multi-modal cancer therapy.

• Quercetin Enhances Angiogenesis and BSCB Integrity After SCI

  2026-04-21

  Liu et al. (2025) demonstrate that quercetin facilitates vascular regeneration and preserves blood-spinal cord barrier (BSCB) structure after spinal cord injury by activating the PI3K/Akt signaling pathway. Their integrated approach combines in vitro and in vivo models to clarify cellular, molecular, and functional outcomes relevant to neurovascular recovery.

452 records 20/31 page Previous Next First page 上5页 1617181920 下5页 Last page